US FDA oncology drug approvals in 2014

被引:5
|
作者
Wolford, Juliet E. [1 ]
Tewari, Krishnansu S. [1 ]
机构
[1] Univ Calif Irvine, Med Ctr, Chao Family NCI Designated Comprehens Canc Ctr, Orange, CA 92868 USA
关键词
accelerated approval; cancer drugs; orphan drug designation; priority review; US FDA; regulatory approval; OLAPARIB MAINTENANCE THERAPY; OVARIAN-CANCER; DOUBLE-BLIND; MULTICENTER; BEVACIZUMAB; IPILIMUMAB; NIVOLUMAB; IBRUTINIB; MELANOMA;
D O I
10.2217/FON.15.106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer is a close second to heart disease for cause of death in the USA, and could soon surpass heart disease as the population ages and the incidence of cancer continues to increase. While heart disease can be addressed through behavior modification and education (e. g., smoking cessation, dietary changes, exercises that promote cardiovascular fitness), pharmacology and improved surgical devices and methods, cancer ultimately requires improved and novel drug treatments to bring mortality rates down. In 2014, the US FDA approved 17 drugs and/or drug combinations in 12 disease sites for a total of 19 indications in melanoma, hematologic malignancies, gastrointestinal carcinoma, non-small-cell lung cancer, gynecologic malignancies and lymphoma/lymphoproliferative disorders.
引用
收藏
页码:1931 / 1945
页数:15
相关论文
共 50 条
  • [1] 2014 FDA drug approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2015, 14 : 77 - 81
  • [2] 2014 FDA drug approvals
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) : 77 - 81
  • [3] US FDA Drug Approvals for Gynecological Malignancies: A Decade in Review
    Arora, Shaily
    Narayan, Preeti
    Ison, Gwynn
    Berman, Tara
    Suzman, Daniel L.
    Wedam, Suparna
    Prowell, Tatiana M.
    Ghosh, Soma
    Philip, Reena
    Osgood, Christy L.
    Gao, Jennifer J.
    Shah, Mirat
    Krol, Danielle
    Wahby, Sakar
    Royce, Melanie
    Brus, Christina
    Bloomquist, Erik W.
    Fiero, Mallorie H.
    Tang, Shenghui
    Pazdur, Richard
    Ibrahim, Amna
    Amiri-Kordestani, Laleh
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1058 - 1071
  • [4] US FDA in Line with Japan, Europe for New Drug Approvals
    Printz, Carrie
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2014, 7 (05): : 349 - 349
  • [5] US FDA Drug Approvals for Breast Cancer: A Decade in Review
    Arora, Shaily
    Narayan, Preeti
    Osgood, Christy L.
    Wedam, Suparna
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Shah, Mirat
    Krol, Danielle
    Wahby, Sakar
    Royce, Melanie
    Ghosh, Soma
    Philip, Reena
    Ison, Gwynn
    Berman, Tara
    Brus, Christina
    Bloomquist, Erik W.
    Fiero, Mallorie H.
    Tang, Shenghui
    Pazdur, Richard
    Ibrahim, Amna
    Amiri-Kordestani, Laleh
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1072 - 1086
  • [6] 2016 FDA drug approvals
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (02) : 73 - 76
  • [7] 2015 FDA drug approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2016, 15 : 73 - 76
  • [8] 2013 FDA drug approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2014, 13 : 85 - 89
  • [9] 2011 FDA drug approvals
    Asher Mullard
    Nature Reviews Drug Discovery, 2012, 11 (2) : 91 - 94
  • [10] Recent FDA drug approvals
    Naccari, Christopher
    CNS SPECTRUMS, 2008, 13 (06) : 466 - 466